MedTrace Logo

Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis

NCT00429442 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-02-20

No results posted yet for this study

Summary

A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone for at least 3 months

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Simvastatin

80 mg once daily

DRUG

placebo

calcium tablets once daily

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Anna Tsakiri

    lead OTHER

Principal Investigators

  • Jette L Frederiksen, DMSC · Department of Neurology, Glostrup Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Completion
2011-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00429442 on ClinicalTrials.gov